Wolfe Research analyst Rudy Li initiated coverage of Denali Therapeutics (DNLI) with a Peer Perform rating and no price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe cites Denali’s current stock setup for the neutral rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
- Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating
- Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing
- Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley
- Denali Therapeutics assumed with a Buy at UBS